Newborn Sepsis Detection: A Leap Towards Rapid, Painless Diagnosis
The fight against neonatal sepsis, a life-threatening condition affecting newborns, is gaining momentum thanks to innovative research at the University of Calgary. Dr. Richa Pandey, an assistant professor in Biomedical Engineering, is pioneering a recent approach to sepsis detection, moving away from lengthy blood cultures towards a rapid, minimally invasive diagnostic tool.
From Glucose Monitoring to Sepsis Screening
Dr. Pandey’s inspiration stemmed from observing the routine heel-prick blood tests used to monitor glucose levels in at-risk newborns. Recognizing the simplicity and minimal invasiveness of this technique, she questioned whether it could be adapted to screen for sepsis. Currently, diagnosing sepsis relies on blood tests, but results can seize up to 72 hours, leading doctors to often initiate broad-spectrum antibiotic treatment preemptively.
“The emphasis on empiric antibiotic use is driven by long time to get results from the blood culture, but this approach can contribute to antimicrobial resistance. Our test will reduce that,” explains Dr. Pandey.
A Credit Card-Sized Solution
The device under development is remarkably compact – about the size of a credit card – making it suitable for use in diverse settings, including remote locations and resource-limited environments. Instead of measuring glucose, this device aims to detect multiple sepsis biomarkers simultaneously from just a few drops of blood or saliva.
This approach promises to reduce pain for newborns requiring testing and significantly shorten the time to diagnosis. The potential to detect antimicrobial resistance linked to commonly used antibiotics is another significant advantage.
How the Technology Works: Biomarkers and Bioreceptors
The core of Dr. Pandey’s innovation lies in the interaction between biomarkers – indicators of sepsis – and bioreceptors. These biological components specifically recognize and bind to the target molecules, enabling their detection. Her team, including postdoctoral associate Dr. Paul Williamson and graduate student Aamena Yusuf, is currently focused on validating this interaction and integrating the system onto sensors for reliable detection.
The One Child Every Child Initiative
This research is part of the One Child Every Child Platform Advancements in Technology for Child Health (PATCH) program. PATCH focuses on developing scalable technology solutions for paediatric and maternal health, fostering collaboration between clinicians, researchers, and industry partners.
Seeking Clinical Partnerships for Validation
Dr. Pandey’s team is actively seeking clinical partners to support preclinical and feasibility studies. Preclinical studies will assess the test’s performance with clinical samples, while feasibility studies will evaluate its usability and practical application in a hospital setting.
Future Trends in Neonatal Diagnostics
Dr. Pandey’s operate represents a broader trend towards point-of-care diagnostics and personalized medicine in neonatal care. Expect to see increased development in:
- Lab-on-a-Chip Technology: Miniaturized devices like Dr. Pandey’s will become more prevalent, offering rapid, on-site analysis.
- Biosensors for Multiple Biomarkers: Detecting a panel of biomarkers will provide a more comprehensive and accurate assessment of a baby’s condition.
- Saliva-Based Diagnostics: Non-invasive saliva tests will reduce discomfort for newborns and simplify the testing process.
- Artificial Intelligence (AI) Integration: AI algorithms will analyze biomarker data to provide faster and more accurate diagnoses.
Did you understand?
In the United States, more than 18 babies under 28 days old die from sepsis each day, highlighting the urgent demand for improved diagnostic tools.
Frequently Asked Questions
Q: What is neonatal sepsis?
A: Neonatal sepsis is a serious, potentially life-threatening infection that occurs in newborns within the first 28 days of life.
Q: How is sepsis currently diagnosed?
A: Currently, sepsis is diagnosed using blood tests, but results can take several days.
Q: What are biomarkers?
A: Biomarkers are measurable indicators of a biological state or condition, such as the presence of an infection.
Q: What is the PATCH program?
A: PATCH is a program focused on developing technology solutions for paediatric and maternal health.
Q: How will this new device help?
A: This device aims to provide a rapid, minimally invasive diagnosis of sepsis, reducing the need for broad-spectrum antibiotics and improving patient outcomes.
Pro Tip: Early detection is crucial in treating sepsis. If you notice any signs of infection in a newborn, seek immediate medical attention.
Want to learn more about advancements in biomedical engineering? Explore our other articles or subscribe to our newsletter for the latest updates.
